ERNA-102 / Ernexa Therapeutics, Factor Bioscience - LARVOL DELTA

Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease (GlobeNewswire) - "Eterna Therapeutics...announced the company’s new name: Ernexa Therapeutics...The new name reflects the company’s laser-focused mission and ambitious vision...Ernexa has two cell therapy products in development, which are undergoing preclinical trials. Its lead cell therapy product, ERNA-101, is engineered to enhance and regulate the immune system’s response, enabling it to identify and eliminate cancer cells. ERNA-102 is designed to combat inflammation and treat autoimmune disease....Ernexa’s ticker symbol will remain as ERNA."

Commercial • Immunology • Ovarian Cancer • Rheumatoid Arthritis